Al-Yafeai Zaki, Ali Shafaqat, Brown Jimmy, Venkataraj Maamannan, Bhuiyan Md Shenuarin, Mosa Faisal Abu Saleh, Densmore Kenneth, Goeders Nicholas E, Bailey Steven R, Conrad Steven A, Vanchiere John A, Orr A Wayne, Kevil Christopher G, Nobel Bhuiyan Mohammad Alfrad
Department of Medicine, Louisiana State University Health Sciences Center at Shreveport, Shreveport, Louisiana, USA.
Department of Pathology and Translational Pathobiology, Louisiana State University Health Sciences Center at Shreveport, Shreveport, Louisiana, USA.
JACC Adv. 2024 Mar 13;3(7):100840. doi: 10.1016/j.jacadv.2024.100840. eCollection 2024 Jul.
Methamphetamine is an emerging drug threat. The disparity in cardiomyopathy-associated hospital admissions among methamphetamine users (CAHMA) over the decade remains unknown.
The purpose of this study was to determine the trends and prevalence of CAHMA by age, sex, race, and geographical region.
We used data from 2008 to 2020 from the National Inpatient Sample database. We identified 12,845,919 cardiomyopathy-associated hospital admissions; among them, 222,727 were diagnosed as methamphetamine users. A generalized linear model with binomial link function was used to compute the prevalence ratio and 95% CI. Those who used other substances along with methamphetamine were excluded from the analysis.
CAHMA increased by 231% ( trend <0.001) from 2008 to 2020. CAHMA increased 345% for men ( trend <0.001) and 122% for women ( trend <0.001), 271% for non-Hispanic White ( trend <0.001), 254% for non-Hispanic Black (p trend <0.001), 565% for Hispanic ( trend <0.001), and 645% for non-Hispanic Asian ( trend <0.001) population. CAHMA also increased significantly in the West region (530%) ( trend <0.001) and South region (200%) ( trend <0.001) of the United States. Men, Hispanic population, age groups 26 to 40 and 41 to 64 years, and Western regions showed a significantly higher uptrend than their counterparts ( trend <0.001).
CAHMA have increased significantly in the United States. Men, Hispanics, non-Hispanic Asian, age groups 41 to 64. and western regions showed a higher proportional increase highlighting gender-based, racial/ethnic, and regional disparities over the study period.
甲基苯丙胺是一种新出现的毒品威胁。过去十年间，甲基苯丙胺使用者中与心肌病相关的住院情况（CAHMA）差异尚不清楚。
本研究旨在确定按年龄、性别、种族和地理区域划分的CAHMA趋势及患病率。
我们使用了来自国家住院样本数据库2008年至2020年的数据。我们确定了12845919例与心肌病相关的住院病例；其中，222727例被诊断为甲基苯丙胺使用者。使用具有二项式链接函数的广义线性模型来计算患病率比值和95%置信区间。分析中排除了同时使用其他物质的甲基苯丙胺使用者。
2008年至2020年，CAHMA增加了231%（趋势<0.001）。男性的CAHMA增加了345%（趋势<0.001），女性增加了122%（趋势<0.001），非西班牙裔白人增加了271%（趋势<0.001），非西班牙裔黑人增加了254%（p趋势<0.001），西班牙裔增加了565%（趋势<0.001），非西班牙裔亚裔增加了645%（趋势<0.001）。美国西部地区（530%）（趋势<0.001）和南部地区（200%）（趋势<0.001）的CAHMA也显著增加。男性、西班牙裔人群、26至40岁和41至64岁年龄组以及西部地区的上升趋势明显高于其他人群（趋势<0.001）。
在美国，CAHMA显著增加。男性、西班牙裔、非西班牙裔亚裔、41至64岁年龄组以及西部地区的比例增加更高，突出了研究期间基于性别、种族/族裔和地区的差异。
